TP53 and cancer: In an elegant way, Nanki et al. enriched cancer organoids by blocking the frequently altered signaling pathways i.e., TP53, RHO, TGF-β and RAS-phosphoinositide 3-kinase (PI3K), which non-mutated normal organoids do not tolerate [83].